Menopause Research 2026
-d67acd1.png/:/cr=t:5.52%25,l:0%25,w:100%25,h:88.95%25/rs=w:1209,h:605,cg:true)
These updates are provided for general informational purposes only and are not a substitute for professional medical advice, diagnosis, or treatment. Links to external websites are provided for reference and convenience only. Menopause Spotlight is not affiliated with, endorsed by, or compensated by the organizations or publications referenced unless explicitly stated.
Estrogen-Only Hormone Therapy Linked to Lower Alzheimer's Risk in New Study
New research from Stanford Medicine suggests that estrogen-only menopausal hormone therapy may be associated with a lower risk of Alzheimer's disease and fewer Alzheimer's-related changes in the brain.
Researchers analyzed data from more than 21,000 women across two large databases, including brain autopsy findings. Among women whose brains were examined after death, those who had reported using estrogen-only menopausal hormone therapy showed significantly fewer of the characteristic brain changes associated with Alzheimer's disease, including amyloid plaques and neurofibrillary tangles.
Overall, researchers reported approximately 35% lower odds of Alzheimer's disease among women who had used estrogen-only hormone therapy compared with women who had not used menopausal hormone therapy. The association remained after researchers accounted for several known Alzheimer's risk factors, including age, APOE4 genetic status, hypertension, education, and race.
The findings are particularly relevant to women who have had a hysterectomy, for whom estrogen can generally be prescribed without a progestogen. However, the researchers were unable to draw conclusions about combined estrogen-plus-progestin therapy because there were too few autopsy cases involving women who had used these formulations.
While the results are encouraging, the study was observational and cannot establish that estrogen therapy prevents Alzheimer's disease. More research is needed to understand how the type, timing, dose, and duration of menopausal hormone therapy may influence brain health and dementia risk.
For now, decisions about hormone therapy should continue to be based on an individual's menopause symptoms, medical history, health risks, and discussion with a qualified healthcare professional rather than its potential use for Alzheimer's prevention.
This summary (posted August 17, 2026) is based on research reported by Stanford Medicine on August 12, 2026, entitled “Study ties estrogen-based menopausal hormone therapy to lower Alzheimer's risk.”
New Nonhormonal Treatment Shows Promise for Hot Flashes
For women experiencing frequent hot flashes and night sweats during menopause, new research is exploring another potential nonhormonal treatment option.
AbCellera recently announced positive top-line Phase 2 results for ABCL635, an investigational, long-acting antibody being developed to treat moderate-to-severe vasomotor symptoms (VMS), commonly known as hot flashes and night sweats. Unlike hormone therapy, ABCL635 is a nonhormonal treatment. It is administered by injection under the skin and is being developed as a longer-acting option.
The randomized, double-blind, placebo-controlled Phase 2 study included 92 postmenopausal women who were experiencing an average of approximately 10 moderate or severe hot flashes each day. Participants received either a single 600 mg injection of ABCL635 or placebo. Four weeks after treatment, women receiving ABCL635 experienced an average reduction of 8.8 moderate-to-severe hot flashes per day, compared with a reduction of 3.5 per day among women receiving placebo. That represented an 83% average reduction from baseline in hot-flash frequency in the ABCL635 group, compared with 33% in the placebo group. The treatment also significantly reduced the severity of hot flashes compared with placebo.
Hot flashes and night sweats can have effects that extend well beyond feeling overheated. Nighttime symptoms can interrupt sleep, which may contribute to fatigue, difficulty concentrating, mood changes, and reduced quality of life.
In addition to reducing hot-flash frequency and severity, the study reported meaningful improvements in sleep scores and participants' overall impressions of change.
These findings are particularly interesting because improving nighttime vasomotor symptoms could potentially have broader benefits for women whose sleep is regularly disrupted by menopause.
ABCL635 is an antibody designed to block the neurokinin 3 receptor (NK3R).
This receptor is involved in brain pathways that help regulate body temperature. Changes in these pathways during menopause are thought to contribute to vasomotor symptoms. Other nonhormonal treatments also target this biological pathway, but ABCL635 is being developed as a long-acting antibody treatment, potentially allowing for less frequent dosing.
In this Phase 2 study, significant improvements were observed for four weeks following a single injection.
According to the top-line results released by AbCellera, there were no serious adverse events, severe adverse events, or adverse events that resulted in participants discontinuing the study during the four-week treatment period.
The most commonly reported adverse events that occurred more frequently with ABCL635 than placebo were headache, fatigue, and injection-site reactions.
However, the study was relatively small and evaluated participants for only four weeks following treatment. Larger and longer studies will be needed to provide a more complete understanding of the treatment's safety and effectiveness.
The results are encouraging, but ABCL635 remains an investigational treatment. It has not been approved for the treatment of menopause symptoms. The findings will need to be confirmed in larger Phase 3 clinical trials before regulators can determine whether the treatment is sufficiently safe and effective for wider use.
If future studies confirm these early findings, ABCL635 could potentially provide another option for women seeking nonhormonal treatment for moderate-to-severe hot flashes and night sweats. For now, the Phase 2 findings offer an encouraging glimpse at how the range of menopause treatment options may continue to expand.
ABCL635 is an investigational drug and is not currently approved for the treatment of menopause symptoms. The results discussed here are top-line Phase 2 clinical trial results announced by AbCellera. Additional studies are required to confirm its safety and effectiveness.
This summary (posted August 12, 2026) is based on findings reported by AbCellara in the press release " AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile," published August 10, 2026.
New Study Highlights the Importance of Bone Health After Menopause
A new study published in Menopause suggests that osteoporosis may be associated with an increased risk of death in postmenopausal women, emphasizing the importance of protecting bone health throughout midlife and beyond.
Researchers found that women with osteoporosis and lower femoral bone mineral density had a higher risk of all-cause mortality than women with healthier bone density. The association was particularly evident within specific ranges of bone mineral density, suggesting that bone health may provide valuable insights into a woman's overall health and future risk.
Although the study does not prove that osteoporosis directly causes an increased risk of death, it reinforces the importance of early detection and appropriate management. Bone density screening, weight-bearing exercise, adequate calcium and vitamin D intake, and other evidence-based treatments may all play an important role in maintaining bone health after menopause.
The findings serve as an important reminder that osteoporosis is often called a "silent disease" because bone loss can occur without symptoms until a fracture happens. Regular discussions with a healthcare provider about bone health and individual risk factors are an important part of healthy aging.
This summary (posted August 10, 2026) is based on findings published in Menopause and reported by The Menopause Society in the press release "Osteoporosis Could Prove Deadly in Postmenopausal Women," published May 12, 2026.
Premature Menopause Linked to Higher Risk of High Blood Pressure
A new study published in the journal Menopause suggests that women who experience premature menopause may have a greater risk of developing high blood pressure later in life.
Researchers followed more than 107,000 women and found that women who reached menopause before age 40 had a significantly higher risk of developing hypertension than women who experienced menopause after age 45. The highest risk was observed among women who entered menopause between the ages of 25 and 35.
The findings reinforce growing evidence that the timing of menopause may provide important clues about a woman's future cardiovascular health. Researchers suggest that age at menopause should be considered when assessing long-term heart health, allowing women at higher risk to benefit from earlier blood pressure monitoring, healthy lifestyle measures, and individualized discussions about menopause management.
Although the study found an association rather than proving that premature menopause causes high blood pressure, it highlights the importance of regular cardiovascular health checks for women who experience menopause at an earlier age.
This summary (posted August 5, 2026) is based on findings published in Menopause entitled "Premature menopause is associated with the development of hypertension during follow-up."
Study Compares Menopause Symptoms Across Different Age Groups
A new study published in Menopause compared the burden of menopause symptoms among women at different stages of midlife and found that symptom patterns can vary with age rather than disappear completely after menopause.
Researchers assessed women across several age groups and found that vasomotor symptoms, such as hot flashes and night sweats, remained common during the menopause transition but tended to become less frequent with age. However, other concerns, including vaginal dryness, sleep problems, and musculoskeletal symptoms, often continued into later postmenopause and remained important contributors to quality of life.
The findings highlight that menopause is not a single event but an evolving transition. As hormone levels change over time, the types of symptoms women experience may also change, meaning healthcare needs can differ during perimenopause, early postmenopause, and later postmenopause.
The authors conclude that menopause care should be individualized, with treatment and support tailored to a woman's age, symptoms, and overall health rather than assuming symptoms resolve after menopause.
This summary (posted July 13, 2026) is based on findings published in Menopause and reported by News-Medical entitled "Study compares menopause symptom burden across different age groups."
New Research Suggests the Ovaries May Continue to Play an Important Role After Menopause
For many years, it was believed that the ovaries became largely inactive after menopause. However, a new study published in Molecular Human Reproduction suggests they may continue to play an important role in the body long after reproductive function ends.
Using advanced molecular techniques in animal models, researchers found that post-reproductive ovaries appear to undergo a remarkable transformation. Rather than remaining dormant, the ovaries showed increased activity in immune-related pathways, suggesting they may shift from a primarily reproductive organ to one involved in immune regulation.
The findings challenge the traditional view that the ovaries have little biological function after menopause and raise new questions about how they may influence healthy aging. Researchers believe this discovery could improve our understanding of menopause and help guide future studies into women's long-term health.
Because this research was conducted primarily in animal models, more studies are needed to determine whether the same changes occur in humans and what they may mean for clinical care.
This summary (posted July 6, 2026) is based on findings published in Molecular Human Reproduction entitled "The post-reproductive ovary shifts from a reproductive to an immune-like organ." published June 10, 2026.
New Research Links Lower Estrogen Levels to More Severe Perimenopausal Migraine
A new study published in The Journal of Headache and Pain suggests that perimenopause may be associated with more frequent and more severe migraine attacks, with lower estrogen levels linked to greater migraine severity.
Researchers compared perimenopausal women with migraine to women without migraine and found that those with migraine had significantly lower estradiol levels, along with more fatigue, sleep disturbances, mood symptoms, and anxiety. Women with lower estradiol levels also reported greater migraine intensity and disability.
The findings add to growing evidence that hormonal fluctuations during the menopause transition may influence migraine severity and quality of life. Although the study cannot prove that declining estrogen causes migraines to worsen, it highlights the important relationship between hormonal changes and brain health during perimenopause.
The authors conclude that greater awareness of perimenopausal migraine and a multidisciplinary approach to care may help improve symptom management and quality of life for affected women.
This summary (posted June 29, 2026) is based on findings published in The Journal of Headache and Pain entitled "Clinical characteristics of perimenopausal migraine and its correlation to hormonal levels." published June 16, 2026.
Study Suggests Surgical Menopause May Lead to More Severe GSM Symptoms
A new study published in Menopause suggests that women who undergo surgical menopause may experience more severe symptoms of genitourinary syndrome of menopause (GSM) than women who reach menopause naturally.
Researchers evaluated more than 400 postmenopausal women and found that those who underwent surgical menopause had higher overall GSM scores and more severe symptoms, including sexual and urinary concerns. Women in the surgical menopause group were also more likely to show physical signs of GSM during clinical examinations.
Surgical menopause occurs when both ovaries are removed, resulting in a sudden decline in estrogen levels. Researchers believe this abrupt hormonal change may contribute to the increased severity of GSM symptoms.
GSM is a common but often underrecognized condition associated with menopause and can include vaginal dryness, irritation, painful intercourse, urinary urgency, recurrent urinary tract infections, and other symptoms that may affect quality of life. The findings highlight the importance of discussing symptoms with a healthcare provider, particularly for women who experience surgical menopause.
This summary (posted June 22, 2026) is based on findings published in Menopause and reported by The Menopause Society in the press release "Surgical Menopause Causes More Severe Genitourinary Syndrome of Menopause Phenotype," published June 10, 2026.
New Study Reinforces the Importance of Timing When Starting Hormone Therapy
A new study published in Menopause examined the health outcomes of more than 83,000 women aged 50 years and older to better understand how the age at which menopausal hormone therapy (HT) is started may influence long-term health.
Researchers found that women who initiated hormone therapy after age 65 had higher risks of certain cancers and vascular events compared with women who never used hormone therapy. The findings support current recommendations that discourage starting systemic hormone therapy later in life unless there is a compelling clinical reason.
The study also reinforces the concept that timing matters. Current menopause guidelines recommend that hormone therapy be individualized and that, for many healthy women with bothersome symptoms, the benefits may outweigh the risks when treatment is started before age 60 or within 10 years of menopause onset.
The authors emphasize that treatment decisions should be based on a woman's symptoms, medical history, personal risk factors, and ongoing discussions with her healthcare provider. As women age, regular reassessment of the risks and benefits of hormone therapy remains essential.
This summary (posted June 15, 2026) is based on findings published in Menopause entitled "Health outcomes of hormone therapy initiated or continued after age 65."
New Study Suggests Swapping Animal Protein for Plant Protein May Support Weight Loss After Menopause
A new study published in the journal Menopause suggests that replacing animal protein with plant-based protein may help support weight loss in postmenopausal women, without reducing overall protein intake.
Researchers analyzed dietary changes in postmenopausal women participating in a 12-week randomized clinical trial. Women following a low-fat vegan diet that included daily soybeans naturally replaced animal protein with plant protein while maintaining a similar total protein intake.
The findings showed that women who shifted their protein sources experienced greater weight loss. A reduction of approximately 16 grams of animal protein and an increase of around 13 grams of plant protein per day was associated with an average weight loss of about 1 kilogram (2.2 pounds).
The researchers suggest that the source of protein may be just as important as the amount consumed. Foods such as beans, lentils, soy products, and whole grains may offer metabolic benefits while supporting healthy weight management during the menopause transition.
While this study adds to growing evidence supporting plant-forward eating patterns, it does not suggest that women need to eliminate animal products entirely. Individual nutritional needs vary, and dietary changes should be tailored to personal preferences and health conditions.
What this means for you:
- Replacing some animal protein with plant-based alternatives may support healthy weight management after menopause.
- Beans, lentils, soy foods, and whole grains are nutritious sources of plant protein.
- Overall dietary pattern, regular physical activity, and strength training remain important components of maintaining a healthy weight and preserving muscle mass during menopause.
This summary (posted June 12, 2026) is based on findings published in Menopause entitled " Plant protein and body weight in postmenopausal women: a secondary analysis from a randomized clinical trial" originally published on June 9, 2026
New Global Study Links Early Menopause to Increased Cardiovascular Risk
A large international study published in The Lancet Obstetrics, Gynaecology, & Women’s Health has found that women who experience premature or early menopause may have a higher risk of cardiovascular disease compared with women who reach menopause at the typical age.
Researchers analyzed data from the multinational Prospective Urban Rural Epidemiology (PURE) study, which included women from countries with varying income levels and diverse ethnic backgrounds. The aim of the study was to estimate the prevalence of premature menopause and examine its association with major cardiovascular events.
The findings suggest that women who experience menopause before the age of 40, and those with early menopause before age 45, may have an increased risk of heart attack, stroke, heart failure, or cardiovascular death later in life.
The authors emphasize that menopause timing should be considered an important factor when assessing a woman's long-term cardiovascular health. Recognizing women at higher risk may allow earlier lifestyle interventions, risk factor management, and preventive care.
While menopause itself is a natural part of aging, the study highlights the importance of monitoring cardiovascular health, particularly for women who experience menopause earlier than expected.
This summary (posted June 10, 2026) is based on findings published in The Lancet Obstetrics, Gynaecology, & Women’s Health entitled "Early menopause and its association with cardiovascular outcomes (PURE): a multinational prospective cohort study."
New Research Highlights the Impact of ADHD Across a Woman's Reproductive Life
A new review published in Archives of Women's Mental Health highlights how hormonal changes throughout a woman's life may influence attention-deficit/hyperactivity disorder (ADHD) symptoms, including during menstruation, pregnancy, perimenopause, and menopause.
Researchers found that fluctuations in estrogen levels can affect dopamine and other brain pathways involved in attention, memory, and emotional regulation. As estrogen declines during the menopause transition, many women with ADHD report worsening symptoms such as difficulty concentrating, forgetfulness, emotional dysregulation, and executive function challenges. Some women may first recognize ADHD during midlife as hormonal changes make previously manageable symptoms more noticeable.
The review emphasizes the importance of greater awareness among healthcare professionals and the need for individualized treatment approaches that consider both hormonal status and neurodevelopmental conditions.
Although more research is needed, the findings suggest that understanding the interaction between hormones and ADHD may help improve diagnosis, support, and quality of life for women throughout the reproductive lifespan.
This summary (posted June 8, 2026) is based on findings published in Archives of Women's Mental Health entitled "Attention-deficit/hyperactivity disorder across the female reproductive lifespan." Additional reporting was provided by the New York Post.
Additional coverage: New York Post
New Study Explores Possible Link Between GLP-1 Medications and Lower Breast Cancer Risk
A new study suggests that GLP-1 medications, commonly prescribed for weight loss and type 2 diabetes, may be associated with a lower risk of breast cancer in women with obesity aged 45 to 80 years.
Researchers analyzed health data from more than 110,000 women and found that those taking GLP-1 medications had a lower incidence of breast cancer compared with women who were not using these treatments. Scientists believe the potential benefit may be related to weight loss, changes in metabolism, or other biological effects of the medications, although the exact mechanism remains unclear.
Importantly, the study was observational, meaning it cannot determine whether GLP-1 medications directly reduce breast cancer risk. Further clinical trials are needed before these medications can be considered for cancer prevention.
The findings add to growing research exploring the wider health effects of GLP-1 therapies beyond weight management and diabetes treatment and may help inform future strategies for improving women's health.
This summary (posted June 2026) is based on research reported by ScienceDaily entitled "GLP-1 medications associated with lower breast cancer risk in women with obesity," originally published June 5, 2026.
Additional coverage: ScienceDaily
Fertility History May Offer Clues About Menopause Timing
A new study published in Menopause suggests that women with a history of primary infertility may be at increased risk of experiencing menopause earlier than women without infertility.
Researchers followed nearly 700 women and found that those with primary infertility underwent natural menopause approximately one year earlier on average. The increased risk was most apparent among women with unexplained infertility and those with a history of endometriosis. The study did not find a significant association between infertility and premature menopause, which occurs before age 40.
The findings are important because early menopause (before age 45) has been linked to long-term health concerns, including cardiovascular disease, osteoporosis, and cognitive decline. Researchers suggest that women with a history of primary infertility may benefit from counseling and monitoring for signs of early menopause.
Although more research is needed, the study highlights the close relationship between reproductive health and healthy aging.
This summary (posted June 5, 2026) is based on findings originally published in Menopause entitled " Infertility and age of menopause in a longitudinal cohort of women with primary infertility." was provided by Medscape and The Menopause Society. Originally published June 4, 2026.
Additional coverage: Medscape
New Research Links Longer Reproductive Lifespan to Better Brain Health
A new study published in Aging Cell suggests that women who spend more years in their reproductive phase may experience slower brain aging later in life.
Researchers analyzed brain scans from more than 1,000 postmenopausal women and found that those who had a longer reproductive lifespan, either because they started menstruating earlier, experienced menopause later, or both, showed signs of better brain health compared with women who had fewer reproductive years.
Scientists believe estrogen may play a role in protecting the brain. Estradiol, the primary form of estrogen during a woman's reproductive years, has been shown in previous research to support communication between brain cells, reduce inflammation, and promote neuroplasticity.
The findings add to growing evidence that menopause is not only a reproductive transition but also a neurological one. While the study does not prove that longer estrogen exposure directly prevents cognitive decline, it suggests that reproductive history may influence how the brain ages.
Researchers note that more studies are needed to better understand the relationship between hormones, menopause, and long-term brain health.
This summary (posted June 3, 2026) is based on findings originally published on March 23, 2026, in Aging Cell entitled "Longer reproductive lifespan is associated with slower brain aging in postmenopausal women." Additional reporting by Korin Miller published June 2, 2026, provided by Women's Health magazine.
Additional coverage: Women's health
Hormone Therapy May Enhance Weight Loss in Postmenopausal Women
A new Mayo Clinic study published in The Lancet Healthy Longevity suggests that menopausal hormone therapy (MHT) may enhance the effects of the weight-loss medication tirzepatide in postmenopausal women.
Researchers found that women using both hormone therapy and tirzepatide lost about 35% more weight than women taking tirzepatide alone. The study followed 120 adults with overweight or obesity who were treated with tirzepatide for at least 12 months.
Scientists believe the findings may point to a possible interaction between estrogen and GLP-1-based medications, which are commonly prescribed for obesity and type 2 diabetes. Researchers noted that estrogen may help strengthen the appetite-suppressing effects of these medications.
Experts caution that this was an observational study, meaning it cannot prove that hormone therapy directly caused the additional weight loss. Lifestyle factors, sleep quality, and relief of menopause symptoms may also have contributed to the results.
The findings highlight growing interest in more personalized approaches to managing weight and cardiometabolic health after menopause.
This summary (posted May 13, 2026) is based on reporting by Mayo Clinic / ScienceDaily entitled “Hormone therapy may enhance weight loss effects of tirzepatide in postmenopausal women.” Originally published March 23, 2026.
Workplace Support for Menopause Still Limited
Despite growing public conversation about menopause, a new report highlights that workplace support for menopausal employees remains insufficient. According to a news release from The Enquirer / Cincinnati.com, many organizations are only beginning to acknowledge menopause as a workplace issue, even though millions of women experience symptoms that can affect job performance, comfort, and long-term career success.
The article points out that while some employers have started offering more flexible scheduling, wellness programs, and manager training, most workplaces still lack formal policies or education about menopause. Experts stress that this gap leaves many women struggling in silence, especially when symptoms like fatigue, brain fog, sleep disruption, and mood changes affect daily work life.
Advocates say that effective support should include:
- Clear workplace policies on menopause
- Education for managers and HR
- Flexible work arrangements
- Access to health and wellness resources
As menopause becomes less of a taboo topic, employers have an opportunity, and a responsibility, to support employees in navigating this transition. Addressing menopause in the workplace not only improves women’s health and well-being but also contributes to a more inclusive, productive work environment.
This summary (posted February 1, 2026) is based on an EIN Presswire published on Cincinnati.com / The Enquirer entitled “As menopause enters the spotlight, workplace support remains limited.” Originally published January 14, 2026.
Menopause Linked to Changes in the Brain’s Gray Matter
New research reported by Scientific American suggests that menopause is associated with measurable changes in the brain’s gray matter, the tissue involved in memory, thinking, and emotional regulation. Brain imaging studies have shown that some brain regions may shrink during the menopausal transition, particularly areas involved in cognition and memory.
Researchers believe these changes are linked to declining estrogen levels, which play an important role in brain metabolism, blood flow, and neural communication. However, scientists also note that the brain appears capable of adapting after menopause, with signs of recovery and compensation over time.
Experts emphasize that menopause is not just a reproductive transition, it is also a neurological one. Understanding these brain changes could help explain symptoms such as brain fog, mood shifts, and sleep disturbances, and may guide future strategies to protect brain health during midlife and beyond.
This summary (posted January 27, 2026) is based on reporting
by Jackie Flynn Mogenson (edited by Claire Cameron) for Scientific American, originally published January 27, 2026.
Menopause Can Have Intensified Effects for Autistic People
New research from Bournemouth University highlights that menopause can affect autistic individuals in ways that are much more intense and complex than for neurotypical women. The first series of studies of its kind found that the hormonal, emotional, and neurological changes of menopause may dial up aspects of autism, such as sensory sensitivities and focus, to disabling levels, and can also amplify struggles associated with co-occurring ADHD.
Autistic study participants reported that menopause not only affected classic symptoms like hot flashes, but also heightened emotional and sensory responses, making daily living more challenging. Researchers described menopause as a neurological transition that interacts with pre-existing neurological differences, not just a reproductive change.
The findings also revealed that many autistic people face difficulty accessing supportive care during menopause, and some described significant mental health declines, including anxiety, depression, and thoughts of self-harm. Experts say there is a pressing need for tailored healthcare approaches and increased awareness among clinicians about how menopause uniquely impacts neurodivergent people.
This summary (posted January 21, 2026) is based on reporting
by Bournemouth University (edited by Gaby Clark, reviewed by Andrew Zinn) for Medical Express, originally published January 21, 2026.
Age or Type of Menopause Does Not Increase Diabetes Risk
A major new study published in Menopause followed more than 146,000 women for nearly 15 years to explore whether early, premature, or surgical menopause increases the risk of developing type 1 or type 2 diabetes.
Although women with earlier menopause appeared to have higher diabetes rates at first glance, deeper statistical analysis showed no independent or clinically meaningful link between:
- Age at menopause (normal, early, or premature), or
- Type of menopause (natural vs. surgical)
…and the development of diabetes.
In this large, long-term study, menopause timing and type were not risk factors for diabetes once lifestyle and health factors were considered.
This is reassuring news for women who experience early or surgical menopause, and a helpful reminder that diabetes risk is driven more by overall health, weight, physical activity, and metabolic factors than by menopause itself.
This summary (posted January 15, 2026) is based on the research article: Timing and type of menopause are not risk factors for the onset of diabetes: a UK Biobank cohort study by Jose Antonio Quesada PhD. Originally published in Menopause on January 13, 2026.
Strength Training After Menopause: Why It Matters More Than Ever
A recent health report highlights just how essential strength training becomes after menopause, especially as estrogen levels decline and the body naturally loses bone density and muscle mass. Experts note that this shift can accelerate muscle loss and increase the risk of falls, fractures, and mobility challenges if left unaddressed.
The article emphasizes that strength training is one of the most effective ways to maintain:
- Bone health
- Muscle strength
- Metabolism
- Functional mobility
It also offers practical guidance on how to make the most of your workouts, including starting slowly, focusing on proper form, and incorporating a mix of resistance exercises to build strength safely and effectively.
This growing body of evidence reinforces what many women already know firsthand: staying strong is not just about fitness, it’s about maintaining independence, confidence, and long‑term health.
This summary (posted January 12, 2026) is based on reporting by Laura Ungar for The Associated Press, originally published January 10, 2026.
No evidence between MHT and the risk of dementia in postmenopausal women
A new systematic review and meta‑analysis published in The Lancet Healthy Longevity examined whether menopause hormone therapy (MHT) influences the risk of developing mild cognitive impairment or dementia. Dementia affects women at higher rates than men, and many have wondered whether hormonal changes during menopause, or the use of hormone therapy, play a role.
Researchers reviewed more than 5,900 records and analyzed ten high‑quality studies involving over 1 million women. They looked at different types of MHT (including estrogen‑only and combined therapy), timing of use, and duration.
Key Findings:
- MHT did not increase or decrease the risk of mild cognitive impairment or dementia.
- Results were consistent across different types of hormone therapy.
- Timing of initiation and duration of use did not change the outcome.
- No studies evaluated testosterone therapy or MHT use in women with premature ovarian insufficiency.
The findings support the current clinical guidance that MHT should not be prescribed to prevent dementia, but it also does not appear to raise dementia risk.
Decisions about hormone therapy should continue to be based on symptom relief, quality of life, and individual health factors.
The authors note that more long‑term, high‑quality research is needed, especially for women with early menopause, premature ovarian insufficiency, or existing mild cognitive impairment.
This summary (posted January 5, 2026) is based on the research article Menopause hormone therapy and risk of mild cognitive impairment or dementia: a systematic review and meta-analysis, Melville, Melissa et al. The Lancet Healthy Longevity, Volume 6, Issue 12, 100803, originally published December, 2025.
New research continues to deepen our understanding of menopause and women’s health.
Medical Disclaimer
The information on this page is provided for educational purposes only and summarizes research related to menopause and women’s health. Research findings may evolve as new evidence becomes available and should not be interpreted as medical advice or as a recommendation for any specific treatment.
Always consult a qualified healthcare professional about your individual health, symptoms, medications, or treatment options.